Daily Cardiology Research Analysis
A Lancet Commission proposes reframing coronary artery disease as atherosclerotic coronary artery disease (ACAD), shifting focus from ischemia to early atheroma detection and prevention. Large-scale genomics reveals gene-by-sleep duration interactions that influence blood pressure, supporting precision medicine strategies. Mechanistic multi-omics in mitochondrial cardiomyopathy identify ATF3 as a transient regulator of cardiomyocyte transition from compensation to failure.
Summary
A Lancet Commission proposes reframing coronary artery disease as atherosclerotic coronary artery disease (ACAD), shifting focus from ischemia to early atheroma detection and prevention. Large-scale genomics reveals gene-by-sleep duration interactions that influence blood pressure, supporting precision medicine strategies. Mechanistic multi-omics in mitochondrial cardiomyopathy identify ATF3 as a transient regulator of cardiomyocyte transition from compensation to failure.
Research Themes
- Reframing coronary artery disease toward early atherosclerosis detection and prevention
- Gene–environment interactions (sleep duration) shaping blood pressure regulation
- Single-cell and spatial transcriptomics revealing transitional states in cardiomyopathy
Selected Articles
1. The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma.
This Commission reframes coronary artery disease as atherosclerotic coronary artery disease (ACAD), advocating a shift from event- and ischaemia-centric care to early detection, prevention, and disease modification. Modeling suggests that eliminating major behavioral and metabolic risk factors by 2050 could reduce ACAD deaths by 82.1%, while highlighting widening burdens in lower- and upper-middle-income countries without equitable access and screening.
Impact: Represents a paradigm shift with concrete policy and implementation recommendations that could reshape prevention, diagnostics, and research priorities globally.
Clinical Implications: Prioritize early atherosclerosis detection (e.g., risk stratification, imaging for plaque), aggressive risk-factor control, and systematic screening programs; reorient guidelines from ischaemia to atheroma biology.
Key Findings
- Proposes reclassifying CAD as atherosclerotic coronary artery disease (ACAD), shifting focus from ischaemia to early atheroma detection and prevention.
- Modeling forecasts that eliminating/controlling major behavioral and metabolic risk factors by 2050 could reduce ACAD deaths by 82.1% (~8.7 million lives annually).
- Disparities: projected ACAD mortality increases by 19.2% in lower-middle-income and 4.2% in upper-middle-income countries without equitable prevention and screening; calls for expanded research funding and early detection.
Methodological Strengths
- Comprehensive, multidisciplinary synthesis integrating epidemiology, modeling, prevention, diagnostics, and health systems.
- Actionable policy roadmap emphasizing early detection and equitable implementation.
Limitations
- Commission framework without new primary data; relies on modeling and synthesis.
- Implementation feasibility and effectiveness will vary across health systems and require local validation.
Future Directions: Develop scalable early atheroma screening, validate risk-guided imaging strategies, invest in transformative anti-atherosclerotic therapies, and deploy equitable prevention programs in LMICs.
UNLABELLED: Coronary artery disease has long been understood through the paradigm of epicardial coronary artery obstruction, causing myocardial ischaemia (a mismatch between myocardial blood supply and demand). However, this model, which focuses on diagnosing and managing coronary artery disease based on ischaemia and cardiovascular events, is flawed. By the time ischaemia manifests, it is often too late for optimal intervention, limiting the effectiveness of treatment options. Despite decades of medical advances, coro
2. A large-scale genome-wide study of gene-sleep duration interactions for blood pressure in 811,405 individuals from diverse populations.
In a multi-ancestry genome-wide interaction study (n=811,405), investigators identified 22 novel loci where genetic effects on blood pressure depend on sleep duration, with non-overlapping signals for short versus long sleep. Several loci showed population- or sex-specific interactions, implicating neurological, thyroidal, bone metabolism, and hematopoietic pathways in sleep-related BP regulation.
Impact: Establishes a robust genetic foundation for sleep-dependent blood pressure biology at scale, enabling precision prevention strategies that incorporate sleep behaviors.
Clinical Implications: Supports integrating sleep duration assessment into hypertension risk stratification; suggests potential for targeted interventions in genetically susceptible individuals with short or long sleep.
Key Findings
- Identified 22 novel gene-by-sleep duration interaction loci for systolic, diastolic, and pulse pressure across 811,405 participants.
- Short- and long-sleep interaction loci did not overlap (12 for short sleep; 10 for long sleep), indicating distinct biological influences.
- Several loci exhibited population- or sex-specific interactions, implicating neurological, thyroidal, bone metabolism, and hematopoietic pathways for BP regulation tied to sleep.
Methodological Strengths
- Very large, multi-ancestry sample with cross-population genome-wide interaction analyses.
- Rigorous phenotype coverage across three BP traits and evaluation of sex and ancestry-specific effects.
Limitations
- Observational genetic design cannot establish causality; sleep duration likely self-reported in contributing cohorts.
- Functional validation of implicated pathways and loci remains to be completed.
Future Directions: Functional studies of novel loci, mechanistic dissection of short vs long sleep pathways, and clinical trials testing sleep-targeted interventions in genetically at-risk groups.
Although both short and long sleep duration are associated with elevated hypertension risk, our understanding of their interplay with biological pathways governing blood pressure remains limited. To address this, we carried out genome-wide cross-population gene-by-short-sleep and long-sleep duration interaction analyses for three blood pressure traits (systolic, diastolic, and pulse pressure) in 811,405 individuals from diverse population groups. We discovered 22 novel gene-sleep duration interaction loci for blood pressu
3. Atf3 controls transitioning in female mitochondrial cardiomyopathy as identified by spatial and single-cell transcriptomics.
Spatial transcriptomics and snRNA-seq of human MCM tissue, integrated with a cardiac Ndufs6 knockdown mouse model, show cardiomyocytes traverse dynamic states from compensation to severe compromise. A transient surge of ATF3 marks—and mechanistically controls—this transition, positioning ATF3 as a potential therapeutic lever in mitochondrial cardiomyopathy.
Impact: Provides mechanistic insight into the compensation-to-failure transition in mitochondrial cardiomyopathy and identifies ATF3 as a transient regulator and candidate target.
Clinical Implications: Suggests monitoring transitional transcriptional programs and exploring ATF3-modulating strategies to delay or prevent decompensation in mitochondrial cardiomyopathy.
Key Findings
- Cardiomyocytes exhibited the most heterogeneous transcriptional landscape under metabolic stress in human MCM tissue.
- Pseudotime analysis revealed dynamic cellular trajectories from compensation to severe compromise.
- A transient upregulation of ATF3 coincided with—and mechanistically governed—the transition, supported by a cardiac-specific Ndufs6 knockdown mouse model.
Methodological Strengths
- Integration of spatial transcriptomics and snRNA-seq in human tissue with in vivo mouse modeling.
- Trajectory inference capturing transitional disease states at single-cell resolution.
Limitations
- Human component based on a single patient sample, limiting generalizability.
- Therapeutic modulation of ATF3 remains to be validated in preclinical intervention studies.
Future Directions: Validate ATF3’s role across larger human cohorts, define upstream metabolic triggers, and test ATF3-targeted interventions to alter disease trajectories.
Oxidative phosphorylation defects result in now intractable mitochondrial diseases (MD) with cardiac involvement markedly affecting prognosis. The mechanisms underlying the transition from compensation to dysfunction in response to metabolic deficiency remain unclear. Here, we used spatially resolved transcriptomics and single-nucleus RNA sequencing (snRNA-seq) on the heart of a patient with mitochondrial cardiomyopathy (MCM), combined with an MCM mouse model with cardiac-specific Ndufs6 knockdown (FS6KD). Cardiomyocytes demonstrated the most heterogeneous expression landscape among cell types caused by metabolic perturbation, and pseudotime trajectory analysis revealed dynamic cellular states transitioning from compensation to severe compromise. This progression coincided with the transient up-regulation of a transcription factor,